Literature DB >> 25621802

Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion.

K Patrick1, W Lau2, A Gassas1, E McDougall2, J Doyle3, M Ali1, J Krueger1, S Courtney1, C Armstrong1, R M Egeler1, T Schechter1.   

Abstract

Major ABO incompatible BM transplantation carries a risk of acute haemolysis. Red cell depletion reduces this risk but not all incompatible RBC (iRBCs) are removed and in children the residual volume can be significant relative to body weight. We sought to determine the volume of iRBCs that can be safely given to children. All patients receiving fresh BM from a donor with a major ABO blood group mismatch between January 2000 and July 2013 at the Hospital for Sick Children, Toronto, were included. Seventy-eight patients were identified. The median volume of iRBCs transfused was 1.6 mL/kg (range 0.1-10.6 mL/kg). Thirty-five patients had minor haemolytic events and five patients had clinically significant adverse events. Two patients, who received 3.66 and 3.9 mL iRBCs/kg, developed renal impairment and in one case hypoxia and hyperbilirubinaemia. One patient had mild hypotension that resolved with i.v. fluid. Two patients developed hypotension secondary to sepsis and unrelated to BM infusion. Although signs of haemolysis occur, with appropriate hydration and monitoring of renal function, clinically significant adverse events related to the infusion of ABO incompatible BM are rare, and, in this study, were only seen in patients receiving >3 mL/kg of iRBCs per kg.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25621802     DOI: 10.1038/bmt.2014.309

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

Review 1.  Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs.

Authors:  S D Rowley
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

2.  Reducing the variation in performance of antibody titrations.

Authors:  J P AuBuchon; J de Wildt-Eggen; L J Dumont
Journal:  Arch Pathol Lab Med       Date:  2008-07       Impact factor: 5.534

3.  AB0-incompatible allogeneic hematopoietic stem cell transplantation.

Authors:  Nina Worel; Peter Kalhs
Journal:  Haematologica       Date:  2008-11       Impact factor: 9.941

4.  Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems.

Authors:  N Worel; H T Greinix; B Schneider; M Kurz; W Rabitsch; P Knöbl; E Reiter; K Derfler; G Fischer; W Hinterberger; P Höcker; P Kalhs
Journal:  Transfusion       Date:  2000-05       Impact factor: 3.157

5.  How do I approach ABO-incompatible hematopoietic progenitor cell transplantation?

Authors:  Jennifer Daniel-Johnson; Joseph Schwartz
Journal:  Transfusion       Date:  2011-03-07       Impact factor: 3.157

6.  ABO incompatible stem cell transplantation in children does not influence outcome.

Authors:  A M Helming; A Brand; R Wolterbeek; M J D van Tol; R M Egeler; L M Ball
Journal:  Pediatr Blood Cancer       Date:  2007-09       Impact factor: 3.167

7.  Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange.

Authors:  Cameron Curley; Elango Pillai; Kari Mudie; Robyn Western; Cheryl Hutchins; Simon Durrant; Glen A Kennedy
Journal:  Transfusion       Date:  2011-08-16       Impact factor: 3.157

Review 8.  Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.

Authors:  S D Rowley; M L Donato; P Bhattacharyya
Journal:  Bone Marrow Transplant       Date:  2011-09       Impact factor: 5.483

9.  Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.

Authors:  Fumihiko Kimura; Ken Sato; Shinichi Kobayashi; Takashi Ikeda; Hiroshi Sao; Shinichiro Okamoto; Koichi Miyamura; Shinichiro Mori; Hideki Akiyama; Makoto Hirokawa; Hitoshi Ohto; Hiroshi Ashida; Kazuo Motoyoshi
Journal:  Haematologica       Date:  2008-10-02       Impact factor: 9.941

  9 in total
  2 in total

1.  Clinically significant adverse events after major ABO mismatch BMT.

Authors:  R S Nickel; E K Waller; M Qayed; K-Y Chiang
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

2.  Infusion hemolysis after pediatric major ABO-mismatched bone marrow transplant: Comparison of two red blood cell depletion techniques.

Authors:  Robert Sheppard Nickel; Muna Qayed; Diana Worthington-White; Sean R Stowell; Kuang-Yueh Chiang
Journal:  Pediatr Blood Cancer       Date:  2017-11-08       Impact factor: 3.838

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.